Dr Jill Corre speaks to ecancer about daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance in transplant-eligible newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Minimal Residual Disease (MRD) update.

The study found that DARA-based induction/consolidation and maintenance resulted in the deepest and most durable MRD negativity, leading to superior PFS outcomes, including in patients with high-risk cytogenetic abnormalities.